Is ALXO or AVTX more profitable?

Avalo Therapeutics' return on equity of -58.03% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -90.30% -67.28% Avalo Therapeutics N/A -58.03% -48.22%

Does the media favor ALXO or AVTX?

In the previous week, ALX Oncology had 4 more articles in the media than Avalo Therapeutics. MarketBeat recorded 6 mentions for ALX Oncology and 2 mentions for Avalo Therapeutics. ALX Oncology's average media sentiment score of 1.71 beat Avalo Therapeutics' score of 0.94 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALXO or LXRX?

In the previous week, ALX Oncology and ALX Oncology both had 6 articles in the media. ALX Oncology's average media sentiment score of 1.71 beat Lexicon Pharmaceuticals' score of 0.44 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CVAC or ALXO?

ALX Oncology has a consensus target price of $4.60, suggesting a potential upside of 130.00%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ALX Oncology 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation and earnings, CVAC or ALXO?

CureVac has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is CVAC or ALXO more profitable?

CureVac has a net margin of 199.92% compared to ALX Oncology's net margin of 0.00%. CureVac's return on equity of -23.03% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% ALX Oncology N/A -90.30% -67.28%

Which has preferable earnings & valuation, ALXO or SLDB?

Solid Biosciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.13 N/A Solid Biosciences N/A N/A -$174.32M -$1.91 N/A

Is ALXO or SLDB more profitable?

Solid Biosciences' return on equity of -71.35% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -90.30% -67.28% Solid Biosciences N/A -71.35% -60.58%

Does the media favor ALXO or SLDB?

In the previous week, ALX Oncology had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 6 mentions for ALX Oncology and 5 mentions for Solid Biosciences. ALX Oncology's average media sentiment score of 1.71 beat Solid Biosciences' score of 0.92 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solid Biosciences 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ALX Oncology (ALXO) Competitors

$2.00 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

ALXO vs. AVTX, LXRX, CVAC, WVE, and SLDB

Should you buy ALX Oncology stock or one of its competitors? ALX Oncology's main competitors and comparable companies include Avalo Therapeutics (AVTX), Lexicon Pharmaceuticals (LXRX), CureVac (CVAC), WAVE Life Sciences (WVE), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ALX Oncology compare to Avalo Therapeutics?

ALX Oncology (NASDAQ:ALXO) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, ALX Oncology had 4 more articles in the media than Avalo Therapeutics. MarketBeat recorded 6 mentions for ALX Oncology and 2 mentions for Avalo Therapeutics. ALX Oncology's average media sentiment score of 1.71 beat Avalo Therapeutics' score of 0.94 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

ALX Oncology presently has a consensus target price of $4.60, indicating a potential upside of 130.00%. Avalo Therapeutics has a consensus target price of $45.10, indicating a potential upside of 130.22%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Avalo Therapeutics' return on equity of -58.03% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Avalo Therapeutics has higher revenue and earnings than ALX Oncology. Avalo Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Avalo Therapeutics	$59K	17,806.98	-$78.26M	-$4.37	N/A

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 12.4% of ALX Oncology shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Avalo Therapeutics beats ALX Oncology on 8 of the 14 factors compared between the two stocks.

How does ALX Oncology compare to Lexicon Pharmaceuticals?

ALX Oncology (NASDAQ:ALXO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

In the previous week, ALX Oncology and ALX Oncology both had 6 articles in the media. ALX Oncology's average media sentiment score of 1.71 beat Lexicon Pharmaceuticals' score of 0.44 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ALX Oncology has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 12.4% of ALX Oncology shares are held by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has higher revenue and earnings than ALX Oncology. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Lexicon Pharmaceuticals	$41.47M	24.57	-$50.34M	-$0.15	N/A

ALX Oncology currently has a consensus price target of $4.60, indicating a potential upside of 130.00%. Lexicon Pharmaceuticals has a consensus price target of $4.55, indicating a potential upside of 98.69%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe ALX Oncology is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

ALX Oncology and Lexicon Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does ALX Oncology compare to CureVac?

CureVac (NASDAQ:CVAC) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

CureVac has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

In the previous week, ALX Oncology had 6 more articles in the media than CureVac. MarketBeat recorded 6 mentions for ALX Oncology and 0 mentions for CureVac. ALX Oncology's average media sentiment score of 1.71 beat CureVac's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
ALX Oncology	Very Positive

17.3% of CureVac shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 12.4% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to ALX Oncology's net margin of 0.00%. CureVac's return on equity of -23.03% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
ALX Oncology	N/A	-90.30%	-67.28%

ALX Oncology has a consensus target price of $4.60, suggesting a potential upside of 130.00%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Summary

CureVac beats ALX Oncology on 8 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to WAVE Life Sciences?

ALX Oncology (NASDAQ:ALXO) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

ALX Oncology has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, meaning that its share price is 226% less volatile than the broader market.

ALX Oncology has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

ALX Oncology has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
WAVE Life Sciences	$42.73M	23.24	-$204.38M	-$1.09	N/A

ALX Oncology currently has a consensus price target of $4.60, indicating a potential upside of 130.00%. WAVE Life Sciences has a consensus price target of $22.53, indicating a potential upside of 347.01%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 12.4% of ALX Oncology shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, ALX Oncology had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 6 mentions for ALX Oncology and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.87 beat ALX Oncology's score of 1.71 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ALX Oncology	Very Positive
WAVE Life Sciences	Very Positive

Summary

WAVE Life Sciences beats ALX Oncology on 9 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to Solid Biosciences?

ALX Oncology (NASDAQ:ALXO) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

ALX Oncology has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.41, meaning that its stock price is 141% more volatile than the broader market.

Solid Biosciences' return on equity of -71.35% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Solid Biosciences	N/A	-71.35%	-60.58%

ALX Oncology presently has a consensus price target of $4.60, indicating a potential upside of 130.00%. Solid Biosciences has a consensus price target of $18.18, indicating a potential upside of 86.10%. Given ALX Oncology's higher probable upside, research analysts plainly believe ALX Oncology is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Solid Biosciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 12.4% of ALX Oncology shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ALX Oncology had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 6 mentions for ALX Oncology and 5 mentions for Solid Biosciences. ALX Oncology's average media sentiment score of 1.71 beat Solid Biosciences' score of 0.92 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solid Biosciences	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ALX Oncology beats Solid Biosciences on 8 of the 13 factors compared between the two stocks.

Get ALX Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALXO vs. The Competition

Export

Metric	ALX Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$276.55M	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-1.77	11.62	273.16	25.42
Price / Sales	N/A	1,380.91	631.89	104.53
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	4.17	16.92	11.08	6.36
Net Income	-$101.69M	-$22.74M	$3.48B	$349.79M
7 Day Performance	-1.96%	-0.31%	0.13%	-0.80%
1 Month Performance	2.56%	9.80%	7.08%	4.13%
1 Year Performance	70.94%	55.66%	24.67%	15.17%

ALX Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALXO ALX Oncology	2.6839 of 5 stars	$2.00 flat	$4.60 +130.0%	+70.9%	$276.56M	N/A	N/A	40	Positive News
AVTX Avalo Therapeutics	2.8386 of 5 stars	$19.59 +1.7%	$45.10 +130.2%	+110.9%	$1.05B	$59K	N/A	40
LXRX Lexicon Pharmaceuticals	1.726 of 5 stars	$2.33 +0.3%	$4.55 +95.4%	+108.2%	$1.05B	$41.47M	N/A	140
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
WVE WAVE Life Sciences	3.3725 of 5 stars	$5.30 +3.5%	$22.53 +325.1%	-47.5%	$1.04B	$42.73M	N/A	240	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALXO) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALX Oncology (ALXO) Competitors

ALXO vs. AVTX, LXRX, CVAC, WVE, and SLDB

How does ALX Oncology compare to Avalo Therapeutics?

Summary

How does ALX Oncology compare to Lexicon Pharmaceuticals?

Summary

How does ALX Oncology compare to CureVac?

Summary

How does ALX Oncology compare to WAVE Life Sciences?

Summary

How does ALX Oncology compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALX Oncology (ALXO) Competitors

ALXO vs. AVTX, LXRX, CVAC, WVE, and SLDB

How does ALX Oncology compare to Avalo Therapeutics?

Does the media favor ALXO or AVTX?

Which has more risk & volatility, ALXO or AVTX?

Do analysts recommend ALXO or AVTX?

Is ALXO or AVTX more profitable?

Which has preferable earnings and valuation, ALXO or AVTX?

Do insiders & institutionals believe in ALXO or AVTX?

Summary

How does ALX Oncology compare to Lexicon Pharmaceuticals?

Which has more volatility & risk, ALXO or LXRX?

Does the media favor ALXO or LXRX?

Is ALXO or LXRX more profitable?

Do insiders and institutionals believe in ALXO or LXRX?

Which has stronger valuation and earnings, ALXO or LXRX?

Do analysts prefer ALXO or LXRX?

Summary

How does ALX Oncology compare to CureVac?

Which has stronger valuation and earnings, CVAC or ALXO?

Does the media prefer CVAC or ALXO?

Do institutionals & insiders have more ownership in CVAC or ALXO?

Is CVAC or ALXO more profitable?

Do analysts rate CVAC or ALXO?

Which has more risk & volatility, CVAC or ALXO?

Summary

How does ALX Oncology compare to WAVE Life Sciences?

Which has more risk and volatility, ALXO or WVE?

Is ALXO or WVE more profitable?

Which has better valuation and earnings, ALXO or WVE?

Do analysts rate ALXO or WVE?

Do institutionals and insiders believe in ALXO or WVE?

Does the media favor ALXO or WVE?

Summary

How does ALX Oncology compare to Solid Biosciences?

Which has more volatility and risk, ALXO or SLDB?

Is ALXO or SLDB more profitable?

Do analysts recommend ALXO or SLDB?

Which has preferable earnings & valuation, ALXO or SLDB?

Do insiders and institutionals believe in ALXO or SLDB?

Does the media favor ALXO or SLDB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools